NY, NY – Intelisci LLC, a specialized executive search and advisory service company in the biopharmaceutical sector, proudly announces the appointment of Oncology Strategy Executive Rob Drury-Dryden as the newest member of its Scientific Advisory Board.
Rob is the Founder of Precision Biopharma Consultancy and brings a wealth of experience, having served as Senior Director EMEA Oncology Strategy at Janssen Europe, Middle East & Africa, and as Senior Director Global Commercial Strategy for Apalutamide. With a history of roles spanning from Integrated Brand Value Team Lead for Prostate Cancer EMEA to Oncology Business Unit Director at AstraZeneca , Rob's career has been marked by innovative leadership and profound expertise in precision medicine and oncology drug development.
During his tenure at Janssen, Merck Serono and AstraZeneca, Rob played a pivotal role in the development and commercial strategy of notable medications including Lynparza, Erbitux, Balversa, Zytiga, and Erleada, addressing major tumor types and improving patient access to novel treatments. His analytical skills, strategic thinking, and business acumen have been instrumental in executing business transformations and fostering team leadership across international markets.
Matt Tong, CEO of Intelisci LLC, expresses his excitement: "Rob's appointment is a significant milestone for Intelisci. His impressive background and strategic vision in oncology therapy development will be a tremendous asset to our clients, especially as they plan their progression from pivotal trials, and on to commercialization . Rob's deep knowledge and networks gained in the European Oncology ecosystem, offer Intelisci new perspective and extend our advisory and search capabilities and will ultimately enhance the value we can deliver."
Rob's academic foundation includes an MSc in Biochemistry from the University of Aberystwyth and an MBA from EDHEC in Lille, providing him with a solid base for his contributions to the field. Beyond his professional pursuits, Rob's dedication to philanthropy and his passion for sportsmanship in charity events underscore his commitment to making a difference both within and outside the pharmaceutical arena.
Rob's appointment to the Scientific Advisory Board marks a new chapter for Intelisci as the company continues to disrupt traditional executive search.
About Intelisci LLC:
Intelisci LLC is at the forefront of connecting biopharmaceutical companies with top-tier executive talent. Our expertise in strategic advisory services positions us to lead and innovate within the dynamic landscape of the biopharma industry.
Commentaires